Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
Trial Parameters
Brief Summary
This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1/2 and HRD status.
Eligibility Criteria
Patients are eligible to be included in the study, if all the following inclusion criteria are met: * Patients with newly diagnosed histologically confirmed epithelial ovarian cancer: * FIGO stage I-II with a known BRCA1/2 mutation (germline/gBRCA or somatic/tBRCA) * FIGO stage III-IV of any histology * Women aged ≥18 years of age at the time of diagnosis * Patients intended for platinum-based chemotherapy treatment * Patients capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol * Patients consent to provide archival tumor tissue sample Patients are ineligible to be included in the study, if any of the exclusion criteria are met: * Non-epithelial ovarian cancer, borderline tumors, or mucinous histology * Patients with FIGO stage I-II, BRCAwt ovarian cancer